Loading chat...
IN SB0011
Bill
Status
1/3/2017
Primary Sponsor
James Merritt
Click for details
AI Summary
SB 11 Summary
-
Requires state employee health plans, accident and sickness insurance policies, and HMO contracts to cover at least one abuse deterrent opioid analgesic for each available opioid agonist active ingredient.
-
Defines abuse deterrent opioid analgesics as drugs formulated with abuse deterrent properties and supplied with FDA-approved labeling indicating the properties are expected to deter or reduce abuse.
-
Mandates that coverage for brand name and generic abuse deterrent opioids cannot have less favorable dollar limits, copayments, deductibles, or coinsurance than other brand name or generic prescription drugs under the same plan.
-
Prohibits plans from requiring enrollees to use non-abuse deterrent opioids first as a condition of coverage, though utilization review requirements may apply if applied equally to all opioid formulations.
-
Takes effect July 1, 2017 for plans, policies, and contracts issued, entered into, delivered, amended, or renewed after June 30, 2017.
Legislative Description
Coverage for abuse deterrent opioids. Requires that, if an abuse deterrent opioid analgesic is available with a certain active ingredient, state employee health plans, policies of accident and sickness insurance, and health maintenance organization contracts must provide coverage for at least one abuse deterrent opioid analgesic that provides that active ingredient.
Last Action
First reading: referred to Committee on Health and Provider Services
1/3/2017